As VEGF failed to induce pro-angiogenic Ca2+ oscillations in tumor-derived ECFCs (Lodola et al., 2012, 2017; Dragoni et al., 2015b; Zuccolo et al., 2016), a feature which might underpin the primary and secondary resistance to anti-VEGF drugs, TRPC1 (and SOCE) inhibition could represent a promising strategy to interfere with tumor vascularization (Moccia, 2018). The gene discussed is TRPC1; the disease is neoplasm.